TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients of ≥18 years at time of informed consent~2. Patients with a clinical diagnosis of CF and confirmed by genetic testing~3. Diagnosis of treatment naïve or treatment refractory M. abscessus-PD~4. Signed informed consent documentation (indicating an understanding of the purpose and a willingness to meet the requirements for participation in the study)~Exclusion Criteria:~1. FEV1 \<40% predicted~2. Methaemoglobin concentration \> 2%~3. Use of nitric oxide donor medications such as prilocaine, sodium nitroprusside, and nitroglycerine within 30 days of proposed first treatment~4. Use of phosphodiesterase inhibitors (e.g., sildenafil) within 30 days of proposed first treatment~5. Evidence of pulmonary hypertension~6. History of frequent low volume or massive haemoptysis~7. Liver disease (i.e. liver cirrhosis, portal hypertension)~8. Subjects who have undergone organ transplantation~9. Pregnancy or lactation (female participants only)~10. Subjects who will not use appropriate forms of contraception for the duration of the study~11. Contraindication or unable to complete lung function testing~12. Contraindication or unable to tolerate nebulised hypertonic saline~13. Changes to previous NTM antibiotic regimen within two months of first dose of study treatment (or 4 months for clofazimine)~14. Subject has received investigational treatment as part of another interventional clinical trial within two months of the proposed first day of treatment~15. Required antibiotic treatment for a pulmonary exacerbation within 2 weeks of enrolment to the study.~16. Inability to undergo study related activities and / or commitments~17. Any subject who in the opinion of the investigator would not be best served by participating in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (Type: EXPERIMENTAL): Single arm trial involving all patients receiving IMP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
.Inclusion Criteria:~1. Men and women between the ages of 18-65 who meet Diagnostic and Statistical Manual -IV criteria for current cocaine dependence~2. Used cocaine at least four days in the past month~3. Individuals must be in good general health~4. Individuals must be capable of giving informed consent and capable of complying with study procedures~5. Women of child-bearing age must agree to use a method of contraception with proven efficacy, consisting of one of the following: 1) Any form of hormonal contraception; 2) Intra-uterine device; 3) Sterilization; 4) Double-barrier contraception which is a combination of two of the following: condoms, spermicide, diaphragm. Pregnancy tests will be performed monthly and if a woman becomes pregnant, the study medication will be discontinued.~Exclusion Criteria:~1. Individuals who meet DSM-IV-TR criteria for bipolar disorder, schizophrenia, or any psychotic disorder other than transient psychosis due to drug abuse~2. Individuals with any other current Axis I psychiatric disorder as defined by DSM-IV-TR that in the investigator's judgment are unstable, or would be disrupted by study medication, or are likely to require pharmacotherapy during the study period~3. Individuals physiologically dependent on any other drugs (excluding nicotine or cannabis) which require medical intervention~4. Individuals with current psychostimulant abuse or dependence (other than cocaine dependence)~5. Individuals with current suicidal risk~6. Individuals with coronary vascular disease as indicated by history or suspected by abnormal ECG or history of cardiac symptoms~7. Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension (SBP \> 140, diastolic blood pressure \> 90, or heart rate \> 100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated transaminases (\< 3x upper limit of normal are acceptable), or uncontrolled diabetes~8. Individuals with a history of seizures, hyperthyroidism and/or glaucoma~9. History of allergic reaction to study medication~10. Women who are pregnant or nursing~11. Currently being prescribed psychotropic medication by another physician (other than sleep medication)~12. Individuals who are legally mandated (e.g., to avoid incarceration) to participate in substance abuse treatment program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lisdexamfetamine (Type: OTHER): open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Incisionless Ultrasound Guided Thread Carpal Tunnel Release and Mini Open Carpal in Patients With Bilateral Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of bilateral CTS with symptoms including pain, paresthesia's, and weakness of the hand in the median nerve distribution for minimum of 3 months~* Willingness to undergo bilateral carpal tunnel surgical treatment with one side having the TCTR and the other a mini open carpal tunnel release~* Age 18-65 years of age~* Clinical examination findings (compression test, Tinels, Phalens, etc) consistent with carpal tunnel syndrome.~* Persistence of symptoms after 6 weeks of conservative treatment such as splinting, activity modification, and/or injection therapy.~* Electromyographic evidence of mild, moderate, moderately severe, or severe median nerve neuropathy at the wrist~* Able and willing to complete all follow-up appointments~Exclusion Criteria:~* Previous CTS surgical release on any of their hands~* Diabetes mellitus~* Hypothyroidism~* Significant Hand arthritis (rheumatologic or osteoarthritis)~* Pregnancy~* Electromyographic evidence of any condition other than CTS affecting the hand~* Workman's compensation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dominant hand-open Carpal Tunnel Release (Type: OTHER): Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
- Dominant hand-Incisionless thread carpal tunnel release (Type: OTHER): Incisionless thread carpal tunnel release on the dominant hand.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* History of bilateral orchiectomies or ongoing treatment with a GnRH agonist for GnRH antagonist~* Disease progression according to PSA Working Group 2~* Minimum starting PSA (Prostate Specific Antigen) level of 2.0 ng/mL~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1~Exclusion Criteria:~* Symptomatic metastases~* Receiving any other agents for the treatment of prostate cancer except gonadotropin releasing hormone (GnRH) agonist or antagonist within the last 30 days~* Received any investigational cancer treatment agents within the last 30 days~* Prior treatment with docetaxel~* History of diabetes requiring drug therapy~* Current treatment with metformin or metformin treatment within the last year~* History of allergic reaction to metformin~* Have uncontrolled intercurrent illness including, but not limited to ongoing or unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Serum creatinine 1.5mg/dL or greater~* Hepatic impairment~* Need for ongoing treatment with cimetidine~* History of a different malignancy except for the following circumstances: Individuals with a history of other malignancies are eligible of they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: basal cell or squamous cell carcinoma of the skin

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): This is the only arm of this phase 2 open label study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bone MicroArchitecture Abatacept (BMA2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent form,~* Age ≥ 18 years,~* Rheumatoid arthritis diagnosis according to ACR/EULAR 2010 criteria~* Abatacept therapy sub-cutaneous required according EULAR recommendations~* Patients affiliated to health insurance~Exclusion Criteria:~* Other arthritis than rheumatoid arthritis,~* Contraindication to abatacept,~* Concomitant treatment with zoledronic acid (Aclasta®) or denosumab (Prolia®),~* Injection intravenously or intra-articular at the 2nd and 3rd metacarpophalangeal joint of the dominant hand during the 3 months prior to inclusion,~* Prior or planned joint surgery at the 2nd or 3rd metacarpophalangeal joint of the dominant hand over the one year study,~* No recent used of high density contrast material,~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with rheumatoid arthritis. (Type: None): Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Initial Screening and Registration~* Previous diagnosis of acute lymphoblastic leukemia or brain tumor and have been off treatment and in disease-free remission for a minimum of one year; treated at the University of Minnesota Medical Center, Fairview.~* Proficient in English~* Have given informed consent (assent)~After Initial Screening~* Have evidence of attention impairment based on parent report of attention deficit (\> and = 75% on attention deficit hyperactivity disorder \[ADHD\] Index, Hyperactivity, or Cognitive-Problems/Inattention Index of parent-completed attention deficit hyperactivity disorder (ADHD) rating scale \[Conners Parent Rating Scale\] and perform at least 1.0 standard deviations below the mean on Omissions, Commissions, or Variability indexes of the Test of Variables of Attention (TOVA)~* Have an estimated Full Scale IQ score on the Wechsler Abbreviated Scale of Intelligence (WASI) \>55.~Exclusion Criteria:~* Have optic pathway gliomas and/or neurofibromatosis~* Diagnosed with ADD/ADHD prior to their cancer diagnosis~* Currently taking antidepressants or antipsychotics~* Currently being treated with stimulant medication~* Blind~* Have glaucoma~* Have a family or personal history of motor or phonic tics or Tourette syndrome~* Have seizures not controlled by antiepileptic drugs~* Taking an MAO-inhibitor~* Have a history of cardiovascular disease, uncontrolled hypertension, or hyperthyroidism, or current hypertension requiring antihypertensives

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: ACTIVE_COMPARATOR): Administered 1 capsule each day for 1 week, .3 mg/kg dose.
- Placebo (Type: PLACEBO_COMPARATOR): Administered 1 capsule each day for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Management of Balance Impairment in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 50-75~* Meet the diagnostic criteria of Parkinson's disease: UK (United Kingdom) Parkinson's disease society brain bank clinical diagnostic criteria~* Disease severity of Hoehn-Yahr stage: stage I to III~* clinical condition stable, not adjusting medicine in recent 3 months~* no falling episode in recent 1 year~* live independently~Exclusion Criteria:~* already enrolled in another studies~* can't cooperate this evaluation examinations due to poor visual acuity, impaired cognitive function, musculoskeletal system disorder, or psychiatric illness~* any other condition would make participants not to cooperative this study~* can't tolerate acupuncture procedure

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- acupuncture with De Qi (Type: EXPERIMENTAL): all participants in this group will receive the standard procedure of acupuncture.
- Sham acupuncture (Type: SHAM_COMPARATOR): In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cervical Occlusion During Intrauterine Insemination (IUI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing IUI for unexplained infertility in our office: Center for Reproduction and Infertility (Providence, RI)~Exclusion Criteria:~* Abnormal Semenalysis TMC \< 5 million~* Blocked Fallopian tubes

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cervical occulsion (Type: EXPERIMENTAL): Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
- Standard IUI (Type: ACTIVE_COMPARATOR): Insemination with TOmcat catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerance of the Use of InnoCath AB® Hyper-compliant Balloon

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* Patients with peripheral arterial occlusive disease and intended for endovascular therapy in the SFA and/or popliteal artery pars I/II~* Patients suitable for endovascular therapy in the SFA and/or popliteal artery pars I/II with a hyper-compliant balloon without further luminal widening~* Target vessels with a sufficient runoff to the foot with at least one vessel~* Rutherford classification 1-4 if physical and medicinal therapies have not been successful~Exclusion Criteria:~* Aneurysms at the site of inflation~* Application directly in the area of large vessel wall injuries with heavy bleeding~* Rutherford classification 5 and 6

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- InnoCath AB® Balloon (Type: EXPERIMENTAL): endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically proven solid tumour malignancy~* Age \>= 18 years~* Karnofsky performance status \>= 70~* \>= 4 brain metastases, all eligible to be treated with radiosurgery~* All brain metastases \<= 4.0 cm in any diameter~* Pre-treatment contrast enhanced MRI brain \<= 42 days prior to enrollment~* Patient able to provide his/her own written informed consent~Exclusion Criteria:~* Prior radiosurgery, whole brain radiotherapy, or cranial radiotherapy~* Previous surgical resection of brain metastasis (biopsy is allowed)~* Prior chemotherapy ≤ 7 days prior to enrollment~* Planned chemotherapy during radiosurgery~* Leukemia, lymphoma, germ-cell tumour, small-cell lung cancer diagnosis~* Brainstem metastasis~* Leptomeningeal metastases~* Contraindication to MR imaging with contrast~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brain metastases (>= 4) (Type: None): Patients with pathologically proven solid tumour malignancy who have \>=4 brain metastases will be treated with gamma knife radiosurgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Post-operative bleeding according to pre-defined criteria for critical bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 and older~* Chronic kidney disease~* Must be able to do stress test~Exclusion Criteria:~* Must not be mentally disabled~* Unable to provide informed consent~* Unable or unwilling to comply with study protocol or procedures~* Pregnancy or unknown pregnancy status in female of childbearing potential~* Participation in any drug trial during the study period~* Prior enrollment in this study~* Active liver disease~* Currently on β-blocker medication at the time of enrollment~* Known history of asthma exacerbation with β-blocker therapy~* Second or third degree AV nodal block or bradycardia with resting heart rate \<50 bpm~* Prior allograft organ transplantation~* Planned allograft transplantation reasonably foreseen within the active treatment period~* Electrocardiographic left or right bundle branch block~* Permanent implanted pacemaker~* Atrial fibrillation~* Ongoing treatment with any of the following medications: sotalol (Betapace), azimilide (Stedicor), quinidine (Quinidex), disopyramide (Norpace), dofetilide (Tikosyn), ibutilide (Corvert), procainamide (Procanbid), bepridil (Vascor), amiodarone (Cordarone), clarithromycin (Biaxin), erythromycin (Eryc), halofantrine (Halfan), pentamidine (Pentam), sparfloxacin (Zagam), domperidone (Motilium), droperidol (Inapsine), chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), thioridazine (Mellaril), pimozide (Orap), arsenic trioxide (Trisenox), cisapride (Propulsid), lidoflazine (Clinium), and methadone (Dolophine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Study Participants (Type: ACTIVE_COMPARATOR): All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues